{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T16:17:19Z","timestamp":1769357839146,"version":"3.49.0"},"publisher-location":"Cham","reference-count":241,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031598142","type":"print"},{"value":"9783031598159","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-59815-9_23","type":"book-chapter","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:01:55Z","timestamp":1723154515000},"page":"323-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.1007","author":[{"given":"Sebastiaan J.","family":"Vastert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan P.","family":"Canny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott W.","family":"Canna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayfel","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Mellins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"23_CR1","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66:3160\u20139. https:\/\/doi.org\/10.1002\/art.38802.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","volume":"70","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Raychaudhuri S, Thompson SD. Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol. 2018;70:7\u201317. https:\/\/doi.org\/10.1002\/art.40350.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 132","key":"23_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.55563\/clinexprheumatol\/lp2u7g","volume":"39","author":"Q Gao","year":"2021","unstructured":"Gao Q, Yuan Y, Wang Y, et al. Clinical characteristics of macrophage activation syndrome in adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2021;39(Suppl 132):59\u201366. https:\/\/doi.org\/10.55563\/clinexprheumatol\/lp2u7g.","journal-title":"Clin Exp Rheumatol"},{"key":"23_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3899\/jrheum.170955","volume":"45","author":"P Ruscitti","year":"2018","unstructured":"Ruscitti P, Iacono D, Ciccia F, et al. Macrophage activation syndrome in patients affected by adult-onset Still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. J Rheumatol. 2018;45:864\u201372. https:\/\/doi.org\/10.3899\/jrheum.170955.","journal-title":"J Rheumatol"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","volume":"51","author":"P Efthimiou","year":"2021","unstructured":"Efthimiou P, Kontzias A, Hur P, et al. Adult-onset Still\u2019s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51:858\u201374. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.06.004.","journal-title":"Semin Arthritis Rheum"},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/adc.85.5.421","volume":"85","author":"S Sawhney","year":"2001","unstructured":"Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85:421\u20136. https:\/\/doi.org\/10.1136\/adc.85.5.421.","journal-title":"Arch Dis Child"},{"key":"23_CR7","first-page":"459","volume":"63","author":"MH Moradinejad","year":"2011","unstructured":"Moradinejad MH, Ziaee V. The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr. 2011;63:459\u201366.","journal-title":"Minerva Pediatr"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/art.22416","volume":"56","author":"J Bleesing","year":"2007","unstructured":"Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965\u201371. https:\/\/doi.org\/10.1002\/art.22416.","journal-title":"Arthritis Rheum"},{"key":"23_CR9","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133\u20138.","journal-title":"J Rheumatol"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75:481\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208982.","journal-title":"Ann Rheum Dis"},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/acr.23482","volume":"70","author":"M Shimizu","year":"2018","unstructured":"Shimizu M, Mizuta M, Yasumi T, et al. Validation of classification criteria of macrophage activation syndrome in Japanese patients with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2018;70:1412\u20135. https:\/\/doi.org\/10.1002\/acr.23482.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/acr2.11048","volume":"1","author":"EMA Eloseily","year":"2019","unstructured":"Eloseily EMA, Minoia F, Crayne CB, et al. Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis. ACR Open Rheumatol. 2019;1:345\u20139. https:\/\/doi.org\/10.1002\/acr2.11048.","journal-title":"ACR Open Rheumatol"},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acr.23277","volume":"70","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Minoia F, Bohnsack J, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2018;70:409\u201319. https:\/\/doi.org\/10.1002\/acr.23277.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"23_CR14","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46:190\u20137. https:\/\/doi.org\/10.3899\/jrheum.180168.","journal-title":"J Rheumatol"},{"key":"23_CR16","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19:424\u201330.","journal-title":"J Rheumatol"},{"key":"23_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1546-0096-10-40","volume":"10","author":"S Kumar","year":"2012","unstructured":"Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of \u201csuspected\u201d systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J. 2012;10:40. https:\/\/doi.org\/10.1186\/1546-0096-10-40.","journal-title":"Pediatr Rheumatol Online J"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/acr.21625","volume":"64","author":"EM DeWitt","year":"2012","unstructured":"DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64:1001\u201310. https:\/\/doi.org\/10.1002\/acr.21625.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/art.40417","volume":"70","author":"RE Borgia","year":"2018","unstructured":"Borgia RE, Gerstein M, Levy DM, et al. Features, treatment, and outcomes of macrophage activation syndrome in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:616\u201324. https:\/\/doi.org\/10.1002\/art.40417.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","volume":"44","author":"W Wang","year":"2015","unstructured":"Wang W, Gong F, Zhu W, et al. Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin Arthritis Rheum. 2015;44:405\u201310. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.07.007.","journal-title":"Semin Arthritis Rheum"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/MPH.0b013e3181dccbf4","volume":"32","author":"GA Latino","year":"2010","unstructured":"Latino GA, Manlhiot C, Yeung RSM, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol. 2010;32:527\u201331. https:\/\/doi.org\/10.1097\/MPH.0b013e3181dccbf4.","journal-title":"J Pediatr Hematol Oncol"},{"key":"23_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27929","volume":"66","author":"MB Jordan","year":"2019","unstructured":"Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66:e27929. https:\/\/doi.org\/10.1002\/pbc.27929.","journal-title":"Pediatr Blood Cancer"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/ijd.15196","volume":"60","author":"JJ Yang","year":"2020","unstructured":"Yang JJ, Lei DK, Ravi V, et al. Overlap between hemophagocytic lymphohistiocytosis and drug reaction and eosinophilia with systemic symptoms: a review. Int J Dermatol. 2020;60:925. https:\/\/doi.org\/10.1111\/ijd.15196.","journal-title":"Int J Dermatol"},{"key":"23_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ccell.2020.09.019","volume":"38","author":"C Turnquist","year":"2020","unstructured":"Turnquist C, Ryan BM, Horikawa I, et al. Cytokine storms in cancer and COVID-19. Cancer Cell. 2020;38:598\u2013601. https:\/\/doi.org\/10.1016\/j.ccell.2020.09.019.","journal-title":"Cancer Cell"},{"key":"23_CR25","first-page":"343","volume":"35","author":"EM Behrens","year":"2008","unstructured":"Behrens EM, Beukelman T, Gallo L, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35:343\u20138.","journal-title":"J Rheumatol"},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.03.023","volume":"114","author":"R Machowicz","year":"2017","unstructured":"Machowicz R, Janka G, Wiktor-Jedrzejczak W. Similar but not the same: differential diagnosis of HLH and sepsis. Crit Rev Oncol Hematol. 2017;114:1\u201312. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.023.","journal-title":"Crit Rev Oncol Hematol"},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss ES, Girard-Guyonvarc\u2019h C, Holzinger D, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131:1442\u201355. https:\/\/doi.org\/10.1182\/blood-2017-12-820852.","journal-title":"Blood"},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"J-I Henter","year":"2007","unstructured":"Henter J-I, Horne A, Aric\u00f3 M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331. https:\/\/doi.org\/10.1002\/pbc.21039.","journal-title":"Pediatr Blood Cancer"},{"key":"23_CR29","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","volume":"146","author":"A Ravelli","year":"2005","unstructured":"Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005a;146:598\u2013604. https:\/\/doi.org\/10.1016\/j.jpeds.2004.12.016.","journal-title":"J Pediatr"},{"key":"23_CR30","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1002\/art.38769","volume":"66","author":"S Dav\u00ec","year":"2014","unstructured":"Dav\u00ec S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2871\u201380. https:\/\/doi.org\/10.1002\/art.38769.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR31","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","volume":"78","author":"F Minoia","year":"2019","unstructured":"Minoia F, Bovis F, Dav\u00ec S, et al. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2019;78:1357\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215211.","journal-title":"Ann Rheum Dis"},{"key":"23_CR32","doi-asserted-by":"publisher","first-page":"e000161","DOI":"10.1136\/rmdopen-2015-000161","volume":"2","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open. 2016;2:e000161. https:\/\/doi.org\/10.1136\/rmdopen-2015-000161.","journal-title":"RMD Open"},{"key":"23_CR33","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/pbc.21423","volume":"50","author":"CE Allen","year":"2008","unstructured":"Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50:1227\u201335. https:\/\/doi.org\/10.1002\/pbc.21423.","journal-title":"Pediatr Blood Cancer"},{"key":"23_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.semnephrol.2006.09.013","volume":"27","author":"CA Dinarello","year":"2007","unstructured":"Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007;27:98\u2013114. https:\/\/doi.org\/10.1016\/j.semnephrol.2006.09.013.","journal-title":"Semin Nephrol"},{"key":"23_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/icb.2010.158","volume":"89","author":"JR Groom","year":"2011","unstructured":"Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207\u201315. https:\/\/doi.org\/10.1038\/icb.2010.158.","journal-title":"Immunol Cell Biol"},{"key":"23_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","volume":"17","author":"F De Benedetti","year":"2021","unstructured":"De Benedetti F, Prencipe G, Bracaglia C, et al. Targeting interferon-\u03b3 in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021;17:678\u201391. https:\/\/doi.org\/10.1038\/s41584-021-00694-z.","journal-title":"Nat Rev Rheumatol"},{"key":"23_CR37","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.3390\/ijms232112757","volume":"23","author":"LM Ailioaie","year":"2022","unstructured":"Ailioaie LM, Ailioaie C, Litscher G. Biomarkers in systemic juvenile idiopathic arthritis, macrophage activation syndrome and their importance in COVID era. Int J Mol Sci. 2022;23:12757. https:\/\/doi.org\/10.3390\/ijms232112757.","journal-title":"Int J Mol Sci"},{"key":"23_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","volume":"119","author":"M Mizuta","year":"2019","unstructured":"Mizuta M, Shimizu M, Inoue N, et al. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome. Cytokine. 2019;119:182\u20137. https:\/\/doi.org\/10.1016\/j.cyto.2019.03.018.","journal-title":"Cytokine"},{"key":"23_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016a;12:259\u201368. https:\/\/doi.org\/10.1038\/nrrheum.2015.179.","journal-title":"Nat Rev Rheumatol"},{"key":"23_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.39407","volume":"68","author":"AA Grom","year":"2016","unstructured":"Grom AA, Ilowite NT, Pascual V, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016b;68:218\u201328. https:\/\/doi.org\/10.1002\/art.39407.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545\u201355. https:\/\/doi.org\/10.1002\/art.30128.","journal-title":"Arthritis Rheum"},{"key":"23_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/RHU.0b013e3181a4f459","volume":"15","author":"A Zeft","year":"2009","unstructured":"Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol. 2009;15:161\u20134. https:\/\/doi.org\/10.1097\/RHU.0b013e3181a4f459.","journal-title":"J Clin Rheumatol"},{"key":"23_CR43","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant Interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 2019;71:1163\u201373. https:\/\/doi.org\/10.1002\/art.40865.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR44","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.210563","volume":"49","author":"G Giancane","year":"2022","unstructured":"Giancane G, Papa R, Vastert S, et al. Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the pharmachild registry. J Rheumatol. 2022;49:398\u2013407. https:\/\/doi.org\/10.3899\/jrheum.210563.","journal-title":"J Rheumatol"},{"key":"23_CR45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","volume":"156","author":"SH Kardaun","year":"2007","unstructured":"Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609\u201311. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07704.x.","journal-title":"Br J Dermatol"},{"key":"23_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.clindermatol.2020.06.008","volume":"38","author":"AR Cardones","year":"2020","unstructured":"Cardones AR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol. 2020;38:702\u201311. https:\/\/doi.org\/10.1016\/j.clindermatol.2020.06.008.","journal-title":"Clin Dermatol"},{"key":"23_CR47","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022;81:406\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220578.","journal-title":"Ann Rheum Dis"},{"key":"23_CR48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12969-020-0399-1","volume":"18","author":"M Shimizu","year":"2020","unstructured":"Shimizu M, Mizuta M, Okamoto N, et al. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2020;18:2. https:\/\/doi.org\/10.1186\/s12969-020-0399-1.","journal-title":"Pediatr Rheumatol Online J"},{"key":"23_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3899\/jrheum.141261","volume":"42","author":"F Minoia","year":"2015","unstructured":"Minoia F, Dav\u00ec S, Horne A, et al. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol. 2015;42:994\u20131001. https:\/\/doi.org\/10.3899\/jrheum.141261.","journal-title":"J Rheumatol"},{"key":"23_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, et al. Benefit of Anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72:326\u201334. https:\/\/doi.org\/10.1002\/art.41103.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/blood.2021013549","volume":"140","author":"A De Matteis","year":"2022","unstructured":"De Matteis A, Colucci M, Rossi MN, et al. Expansion of CD4dimCD8+ T cells characterizes macrophage activation syndrome and other secondary HLH. Blood. 2022;140:262\u201373. https:\/\/doi.org\/10.1182\/blood.2021013549.","journal-title":"Blood"},{"key":"23_CR52","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","volume":"21","author":"GS Schulert","year":"2020","unstructured":"Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. Genes Immun. 2020;21:169\u201381. https:\/\/doi.org\/10.1038\/s41435-020-0098-4.","journal-title":"Genes Immun"},{"key":"23_CR53","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/acr.21889","volume":"65","author":"Y Kimura","year":"2013","unstructured":"Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65:745\u201352. https:\/\/doi.org\/10.1002\/acr.21889.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"23_CR54","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert GS, Yasin S, Carey B, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71:1943\u201354. https:\/\/doi.org\/10.1002\/art.41073.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR55","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78:1722\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216040.","journal-title":"Ann Rheum Dis"},{"key":"23_CR56","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3899\/jrheum.121233","volume":"40","author":"R Strippoli","year":"2013","unstructured":"Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol. 2013;40:761\u20137. https:\/\/doi.org\/10.3899\/jrheum.121233.","journal-title":"J Rheumatol"},{"key":"23_CR57","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.autrev.2007.11.025","volume":"7","author":"EM Behrens","year":"2008","unstructured":"Behrens EM. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun Rev. 2008;7:305\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2007.11.025.","journal-title":"Autoimmun Rev"},{"key":"23_CR58","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jpeds.2005.12.070","volume":"148","author":"T Avcin","year":"2006","unstructured":"Avcin T, Tse SML, Schneider R, et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006;148:683\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2005.12.070.","journal-title":"J Pediatr"},{"key":"23_CR59","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/rheumatology\/40.11.1285","volume":"40","author":"JL St\u00e9phan","year":"2001","unstructured":"St\u00e9phan JL, Kon\u00e9-Paut I, Galambrun C, et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford). 2001;40:1285\u201392. https:\/\/doi.org\/10.1093\/rheumatology\/40.11.1285.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12969-016-0130-4","volume":"15","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia C, Prencipe G, De Benedetti F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017;15:5. https:\/\/doi.org\/10.1186\/s12969-016-0130-4.","journal-title":"Pediatr Rheumatol Online J"},{"key":"23_CR61","doi-asserted-by":"publisher","first-page":"491567","DOI":"10.1155\/2015\/491567","volume":"2015","author":"N Hashemi-Sadraei","year":"2015","unstructured":"Hashemi-Sadraei N, Vejpongsa P, Baljevic M, et al. Epstein-barr virus-related hemophagocytic lymphohistiocytosis: hematologic emergency in the critical care setting. Case Rep Hematol. 2015;2015:491567. https:\/\/doi.org\/10.1155\/2015\/491567.","journal-title":"Case Rep Hematol"},{"key":"23_CR62","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00002281-200209000-00012","volume":"14","author":"A Ravelli","year":"2002","unstructured":"Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002;14:548\u201352. https:\/\/doi.org\/10.1097\/00002281-200209000-00012.","journal-title":"Curr Opin Rheumatol"},{"key":"23_CR63","first-page":"401","volume":"30","author":"AV Ramanan","year":"2003","unstructured":"Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401\u20133.","journal-title":"J Rheumatol"},{"key":"23_CR64","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","volume":"116","author":"LA Cohen","year":"2010","unstructured":"Cohen LA, Gutierrez L, Weiss A, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010;116:1574\u201384. https:\/\/doi.org\/10.1182\/blood-2009-11-253815.","journal-title":"Blood"},{"key":"23_CR65","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12026-014-8563-7","volume":"60","author":"S Colafrancesco","year":"2014","unstructured":"Colafrancesco S, Priori R, Alessandri C, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60:177\u201383. https:\/\/doi.org\/10.1007\/s12026-014-8563-7.","journal-title":"Immunol Res"},{"key":"23_CR66","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/01.RES.0000247067.34173.1b","volume":"99","author":"CA Schaer","year":"2006","unstructured":"Schaer CA, Schoedon G, Imhof A, et al. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res. 2006;99:943\u201350. https:\/\/doi.org\/10.1161\/01.RES.0000247067.34173.1b.","journal-title":"Circ Res"},{"key":"23_CR67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1600-0609.2004.00318.x","volume":"74","author":"DJ Schaer","year":"2005","unstructured":"Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6\u201310. https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00318.x.","journal-title":"Eur J Haematol"},{"key":"23_CR68","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/003655102762377466","volume":"237","author":"HJ M\u00f8ller","year":"2002","unstructured":"M\u00f8ller HJ, Aerts H, Gr\u00f8nbaek H, et al. Soluble CD163: a marker molecule for monocyte\/macrophage activity in disease. Scand J Clin Lab Invest Suppl. 2002;237:29\u201333. https:\/\/doi.org\/10.1080\/003655102762377466.","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"23_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365513.2011.626868","volume":"72","author":"HJ M\u00f8ller","year":"2012","unstructured":"M\u00f8ller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012;72:1\u201313. https:\/\/doi.org\/10.3109\/00365513.2011.626868.","journal-title":"Scand J Clin Lab Invest"},{"key":"23_CR70","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1189\/jlb.1205756","volume":"80","author":"LK Weaver","year":"2006","unstructured":"Weaver LK, Hintz-Goldstein KA, Pioli PA, et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol. 2006;80:26\u201335. https:\/\/doi.org\/10.1189\/jlb.1205756.","journal-title":"J Leukoc Biol"},{"key":"23_CR71","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/JLB.3A1218-500R","volume":"106","author":"MC Nielsen","year":"2019","unstructured":"Nielsen MC, Andersen MN, Rittig N, et al. The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms. J Leukoc Biol. 2019;106:1129\u201338. https:\/\/doi.org\/10.1002\/JLB.3A1218-500R.","journal-title":"J Leukoc Biol"},{"key":"23_CR72","doi-asserted-by":"publisher","first-page":"300060521104996","DOI":"10.1177\/03000605211049963","volume":"49","author":"G Yang","year":"2021","unstructured":"Yang G, Guo N, Yin J, Wu J. Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J Int Med Res. 2021;49:3000605211049963. https:\/\/doi.org\/10.1177\/03000605211049963.","journal-title":"J Int Med Res"},{"key":"23_CR73","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1039\/c3mt00347g","volume":"6","author":"DB Kell","year":"2014","unstructured":"Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6:748\u201373. https:\/\/doi.org\/10.1039\/c3mt00347g.","journal-title":"Metallomics"},{"key":"23_CR74","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1741-7015-11-185","volume":"11","author":"C Ros\u00e1rio","year":"2013","unstructured":"Ros\u00e1rio C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still\u2019s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185. https:\/\/doi.org\/10.1186\/1741-7015-11-185.","journal-title":"BMC Med"},{"key":"23_CR75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxx031","volume":"29","author":"KF Kernan","year":"2017","unstructured":"Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29:401\u20139. https:\/\/doi.org\/10.1093\/intimm\/dxx031.","journal-title":"Int Immunol"},{"key":"23_CR76","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev-immunol-101320-125839","volume":"41","author":"SP Canny","year":"2022","unstructured":"Canny SP, Orozco SL, Thulin NK, Hamerman JA. Immune mechanisms in inflammatory anemia. Annu Rev Immunol. 2022;41:405. https:\/\/doi.org\/10.1146\/annurev-immunol-101320-125839.","journal-title":"Annu Rev Immunol"},{"key":"23_CR77","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1532-5415.1985.tb05435.x","volume":"33","author":"G Ud\u00e9n","year":"1985","unstructured":"Ud\u00e9n G. Inpatient accidents in hospitals. J Am Geriatr Soc. 1985;33:833\u201341. https:\/\/doi.org\/10.1111\/j.1532-5415.1985.tb05435.x.","journal-title":"J Am Geriatr Soc"},{"key":"23_CR78","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41598-020-59898-0","volume":"10","author":"G Mesquita","year":"2020","unstructured":"Mesquita G, Silva T, Gomes AC, et al. H-Ferritin is essential for macrophages\u2019 capacity to store or detoxify exogenously added iron. Sci Rep. 2020;10:3061. https:\/\/doi.org\/10.1038\/s41598-020-59898-0.","journal-title":"Sci Rep"},{"key":"23_CR79","doi-asserted-by":"publisher","first-page":"12232","DOI":"10.1038\/s41598-020-69031-w","volume":"10","author":"P Ruscitti","year":"2020","unstructured":"Ruscitti P, Di Benedetto P, Berardicurti O, et al. Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. Sci Rep. 2020;10:12232. https:\/\/doi.org\/10.1038\/s41598-020-69031-w.","journal-title":"Sci Rep"},{"key":"23_CR80","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1038\/s41467-022-34560-7","volume":"13","author":"J Jia","year":"2022","unstructured":"Jia J, Wang M, Meng J, et al. Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still\u2019s disease pathogenesis. Nat Commun. 2022;13:6804. https:\/\/doi.org\/10.1038\/s41467-022-34560-7.","journal-title":"Nat Commun"},{"key":"23_CR81","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/art.41635","volume":"73","author":"M Wang","year":"2021","unstructured":"Wang M, Liu M, Jia J, et al. Association of the leukocyte immunoglobulin-like receptor A3 gene with neutrophil activation and disease susceptibility in adult-onset Still\u2019s disease. Arthritis Rheumatol. 2021;73:1033\u201343. https:\/\/doi.org\/10.1002\/art.41635.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR82","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.3389\/fimmu.2018.02995","volume":"9","author":"RA Brown","year":"2018","unstructured":"Brown RA, Henderlight M, Do T, et al. Neutrophils from children with systemic juvenile idiopathic arthritis exhibit persistent proinflammatory activation despite long-standing clinically inactive disease. Front Immunol. 2018;9:2995. https:\/\/doi.org\/10.3389\/fimmu.2018.02995.","journal-title":"Front Immunol"},{"key":"23_CR83","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41590-021-00928-y","volume":"22","author":"P Cheung","year":"2021","unstructured":"Cheung P, Schaffert S, Chang SE, et al. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nat Immunol. 2021;22:711\u201322. https:\/\/doi.org\/10.1038\/s41590-021-00928-y.","journal-title":"Nat Immunol"},{"key":"23_CR84","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1055\/s-2007-999051","volume":"22","author":"J Loscalzo","year":"1996","unstructured":"Loscalzo J. The macrophage and fibrinolysis. Semin Thromb Hemost. 1996;22:503\u20136. https:\/\/doi.org\/10.1055\/s-2007-999051.","journal-title":"Semin Thromb Hemost"},{"key":"23_CR85","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OARRR.S151013","volume":"10","author":"B Lerkvaleekul","year":"2018","unstructured":"Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol. 2018;10:117\u201328. https:\/\/doi.org\/10.2147\/OARRR.S151013.","journal-title":"Open Access Rheumatol"},{"key":"23_CR86","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10020-021-00308-0","volume":"27","author":"K Palmblad","year":"2021","unstructured":"Palmblad K, Schierbeck H, Sundberg E, et al. Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome. Mol Med. 2021;27:48. https:\/\/doi.org\/10.1186\/s10020-021-00308-0.","journal-title":"Mol Med"},{"key":"23_CR87","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/1756-185X.12196","volume":"17","author":"VV Reddy","year":"2014","unstructured":"Reddy VV, Myles A, Cheekatla SS, et al. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis. Int J Rheum Dis. 2014;17:261\u20137. https:\/\/doi.org\/10.1111\/1756-185X.12196.","journal-title":"Int J Rheum Dis"},{"key":"23_CR88","first-page":"220","volume":"78","author":"WA Dik","year":"2020","unstructured":"Dik WA, Heron M. Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases. Neth J Med. 2020;78:220\u201331.","journal-title":"Neth J Med"},{"key":"23_CR89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cyto.2017.04.024","volume":"93","author":"S Buhelt","year":"2017","unstructured":"Buhelt S, Ratzer RL, Christensen JR, et al. Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis. Cytokine. 2017;93:15\u201325. https:\/\/doi.org\/10.1016\/j.cyto.2017.04.024.","journal-title":"Cytokine"},{"key":"23_CR90","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.4049\/jimmunol.182.3.1541","volume":"182","author":"LM Maier","year":"2009","unstructured":"Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182:1541\u20137. https:\/\/doi.org\/10.4049\/jimmunol.182.3.1541.","journal-title":"J Immunol"},{"key":"23_CR91","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau AD, Roskams T, Van Damme-Lombaerts R, et al. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648\u201351. https:\/\/doi.org\/10.1182\/blood-2004-08-2997.","journal-title":"Blood"},{"key":"23_CR92","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.blre.2014.03.002","volume":"28","author":"GE Janka","year":"2014","unstructured":"Janka GE, Lehmberg K. Hemophagocytic syndromes \u2013 an update. Blood Rev. 2014;28:135\u201342. https:\/\/doi.org\/10.1016\/j.blre.2014.03.002.","journal-title":"Blood Rev"},{"key":"23_CR93","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","volume":"160","author":"M Shimizu","year":"2015","unstructured":"Shimizu M, Nakagishi Y, Inoue N, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160:277\u201381. https:\/\/doi.org\/10.1016\/j.clim.2015.06.005.","journal-title":"Clin Immunol"},{"key":"23_CR94","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104:735\u201343. https:\/\/doi.org\/10.1182\/blood-2003-10-3413.","journal-title":"Blood"},{"key":"23_CR95","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.20140964","volume":"212","author":"MR Jenkins","year":"2015","unstructured":"Jenkins MR, Rudd-Schmidt JA, Lopez JA, et al. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212:307\u201317. https:\/\/doi.org\/10.1084\/jem.20140964.","journal-title":"J Exp Med"},{"key":"23_CR96","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0092-8674(03)00855-9","volume":"115","author":"J Feldmann","year":"2003","unstructured":"Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461\u201373. https:\/\/doi.org\/10.1016\/s0092-8674(03)00855-9.","journal-title":"Cell"},{"key":"23_CR97","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/art.23199","volume":"58","author":"MM Hazen","year":"2008","unstructured":"Hazen MM, Woodward AL, Hofmann I, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:567\u201370. https:\/\/doi.org\/10.1002\/art.23199.","journal-title":"Arthritis Rheum"},{"key":"23_CR98","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCGENETICS.114.000526","volume":"7","author":"LJ Martin","year":"2014","unstructured":"Martin LJ, Pilipenko V, Kaufman KM, et al. Whole exome sequencing for familial bicuspid aortic valve identifies putative variants. Circ Cardiovasc Genet. 2014;7:677\u201383. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000526.","journal-title":"Circ Cardiovasc Genet"},{"key":"23_CR99","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","volume":"49","author":"SJ Vastert","year":"2010","unstructured":"Vastert SJ, van Wijk R, D\u2019Urbano LE, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49:441\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kep418.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR100","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1091\/mbc.E16-08-0617","volume":"28","author":"SS Woo","year":"2017","unstructured":"Woo SS, James DJ, Martin TFJ. Munc13-4 functions as a Ca2+ sensor for homotypic secretory granule fusion to generate endosomal exocytic vacuoles. Mol Biol Cell. 2017;28:792\u2013808. https:\/\/doi.org\/10.1091\/mbc.E16-08-0617.","journal-title":"Mol Biol Cell"},{"key":"23_CR101","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1002\/art.23734","volume":"58","author":"K Zhang","year":"2008","unstructured":"Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892\u20136. https:\/\/doi.org\/10.1002\/art.23734.","journal-title":"Arthritis Rheum"},{"key":"23_CR102","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11926-014-0439-2","volume":"16","author":"M Zhang","year":"2014","unstructured":"Zhang M, Behrens EM, Atkinson TP, et al. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep. 2014;16:439. https:\/\/doi.org\/10.1007\/s11926-014-0439-2.","journal-title":"Curr Rheumatol Rep"},{"key":"23_CR103","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/art.40438","volume":"70","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Zhang M, Husami A, et al. Brief report: novel UNC13D intronic variant disrupting an NF-\u03baB enhancer in a patient with recurrent macrophage activation syndrome and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70:963\u201370. https:\/\/doi.org\/10.1002\/art.40438.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR104","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ni1431","volume":"8","author":"MM M\u00e9nager","year":"2007","unstructured":"M\u00e9nager MM, M\u00e9nasch\u00e9 G, Romao M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol. 2007;8:257\u201367. https:\/\/doi.org\/10.1038\/ni1431.","journal-title":"Nat Immunol"},{"key":"23_CR105","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1182\/blood-2009-06-225359","volume":"114","author":"SM Wood","year":"2009","unstructured":"Wood SM, Meeths M, Chiang SCC, et al. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood. 2009;114:4117\u201327. https:\/\/doi.org\/10.1182\/blood-2009-06-225359.","journal-title":"Blood"},{"key":"23_CR106","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1074\/jbc.M115.705871","volume":"291","author":"JL Johnson","year":"2016","unstructured":"Johnson JL, He J, Ramadass M, et al. Munc13-4 is a Rab11-binding protein that regulates Rab11-positive vesicle trafficking and docking at the plasma membrane. J Biol Chem. 2016;291:3423\u201338. https:\/\/doi.org\/10.1074\/jbc.M115.705871.","journal-title":"J Biol Chem"},{"key":"23_CR107","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1083\/jcb.201411093","volume":"210","author":"MR Marshall","year":"2015","unstructured":"Marshall MR, Pattu V, Halimani M, et al. VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity. J Cell Biol. 2015;210:135\u201351. https:\/\/doi.org\/10.1083\/jcb.201411093.","journal-title":"J Cell Biol"},{"key":"23_CR108","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1172\/JCI40732","volume":"119","author":"M C\u00f4te","year":"2009","unstructured":"C\u00f4te M, M\u00e9nager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009;119:3765\u201373. https:\/\/doi.org\/10.1172\/JCI40732.","journal-title":"J Clin Invest"},{"key":"23_CR109","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/tra.12244","volume":"16","author":"FE Sepulveda","year":"2015","unstructured":"Sepulveda FE, Burgess A, Heiligenstein X, et al. LYST controls the biogenesis of the endosomal compartment required for secretory lysosome function. Traffic. 2015;16:191\u2013203. https:\/\/doi.org\/10.1111\/tra.12244.","journal-title":"Traffic"},{"key":"23_CR110","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1083\/jcb.141.5.1121","volume":"141","author":"W Faigle","year":"1998","unstructured":"Faigle W, Raposo G, Tenza D, et al. Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome. J Cell Biol. 1998;141:1121\u201334. https:\/\/doi.org\/10.1083\/jcb.141.5.1121.","journal-title":"J Cell Biol"},{"key":"23_CR111","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.4049\/jimmunol.1501284","volume":"196","author":"M Zhang","year":"2016","unstructured":"Zhang M, Bracaglia C, Prencipe G, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis. J Immunol. 2016;196:2492\u2013503. https:\/\/doi.org\/10.4049\/jimmunol.1501284.","journal-title":"J Immunol"},{"key":"23_CR112","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/BOR.0000000000000422","volume":"29","author":"P Tsoukas","year":"2017","unstructured":"Tsoukas P, Canna SW. No shortcuts: new findings reinforce why nuance is the rule in genetic autoinflammatory syndromes. Curr Opin Rheumatol. 2017;29:506\u201315. https:\/\/doi.org\/10.1097\/BOR.0000000000000422.","journal-title":"Curr Opin Rheumatol"},{"key":"23_CR113","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1172\/JCI43157","volume":"121","author":"EM Behrens","year":"2011","unstructured":"Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121:2264\u201377. https:\/\/doi.org\/10.1172\/JCI43157.","journal-title":"J Clin Invest"},{"key":"23_CR114","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3389\/fimmu.2019.03089","volume":"10","author":"J Vandenhaute","year":"2019","unstructured":"Vandenhaute J, Wouters CH, Matthys P. Natural killer cells in systemic autoinflammatory diseases: a focus on systemic juvenile idiopathic arthritis and macrophage activation syndrome. Front Immunol. 2019;10:3089. https:\/\/doi.org\/10.3389\/fimmu.2019.03089.","journal-title":"Front Immunol"},{"key":"23_CR115","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01659","volume":"3","author":"DK Sojka","year":"2014","unstructured":"Sojka DK, Plougastel-Douglas B, Yang L, et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. elife. 2014;3:e01659. https:\/\/doi.org\/10.7554\/eLife.01659.","journal-title":"elife"},{"key":"23_CR116","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1067\/mpd.2003.110","volume":"142","author":"AA Grom","year":"2003","unstructured":"Grom AA, Villanueva J, Lee S, et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142:292\u20136. https:\/\/doi.org\/10.1067\/mpd.2003.110.","journal-title":"J Pediatr"},{"key":"23_CR117","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/art.39933","volume":"69","author":"K Put","year":"2017","unstructured":"Put K, Vandenhaute J, Avau A, et al. Inflammatory gene expression profile and defective interferon-\u03b3 and Granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients. Arthritis Rheumatol. 2017;69:213\u201324. https:\/\/doi.org\/10.1002\/art.39933.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR118","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2014.05.005","volume":"26","author":"A Avau","year":"2015","unstructured":"Avau A, Put K, Wouters CH, Matthys P. Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis. Cytokine Growth Factor Rev. 2015;26:35\u201345. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.05.005.","journal-title":"Cytokine Growth Factor Rev"},{"key":"23_CR119","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1002\/art.39295","volume":"67","author":"L Cifaldi","year":"2015","unstructured":"Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67:3037\u201346. https:\/\/doi.org\/10.1002\/art.39295.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR120","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/1529-0131(200104)44:4<884::AID-ANR145>3.0.CO;2-4","volume":"44","author":"K Shibatomi","year":"2001","unstructured":"Shibatomi K, Ida H, Yamasaki S, et al. A novel role for Interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum. 2001;44:884\u201392. https:\/\/doi.org\/10.1002\/1529-0131(200104)44:4<884::AID-ANR145>3.0.CO;2-4.","journal-title":"Arthritis Rheum"},{"key":"23_CR121","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/art.24750","volume":"60","author":"W de Jager","year":"2009","unstructured":"de Jager W, Vastert SJ, Beekman JM, et al. Defective phosphorylation of Interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2782\u201393. https:\/\/doi.org\/10.1002\/art.24750.","journal-title":"Arthritis Rheum"},{"key":"23_CR122","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/acr2.11426","volume":"4","author":"T Ohya","year":"2022","unstructured":"Ohya T, Nishimura K, Murase A, et al. Impaired Interleukin-18 signaling in natural killer cells from patients with systemic juvenile idiopathic arthritis. ACR Open Rheumatol. 2022;4:503\u201310. https:\/\/doi.org\/10.1002\/acr2.11426.","journal-title":"ACR Open Rheumatol"},{"key":"23_CR123","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802.","journal-title":"N Engl J Med"},{"key":"23_CR124","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"key":"23_CR125","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1146\/annurev-immunol-032414-112227","volume":"33","author":"AA de Jesus","year":"2015","unstructured":"de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol. 2015;33:823\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-032414-112227.","journal-title":"Annu Rev Immunol"},{"key":"23_CR126","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia C, de Graaf K, Pires Marafon D, et al. Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76:166\u201372. https:\/\/doi.org\/10.1136\/annrheumdis-2015-209020.","journal-title":"Ann Rheum Dis"},{"key":"23_CR127","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","volume":"13","author":"A Ravelli","year":"2012","unstructured":"Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289\u201398. https:\/\/doi.org\/10.1038\/gene.2012.3.","journal-title":"Genes Immun"},{"key":"23_CR128","doi-asserted-by":"publisher","first-page":"894846","DOI":"10.3389\/fped.2022.894846","volume":"10","author":"MM Kostik","year":"2022","unstructured":"Kostik MM, Isupova EA, Belozerov K, et al. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis. Front Pediatr. 2022;10:894846. https:\/\/doi.org\/10.3389\/fped.2022.894846.","journal-title":"Front Pediatr"},{"key":"23_CR129","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3899\/jrheum.140288","volume":"42","author":"S Yokota","year":"2015","unstructured":"Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42:712\u201322. https:\/\/doi.org\/10.3899\/jrheum.140288.","journal-title":"J Rheumatol"},{"key":"23_CR130","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00296-011-2249-4","volume":"32","author":"CM Hedrich","year":"2012","unstructured":"Hedrich CM, Bruck N, Fiebig B, Gahr M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int. 2012;32:3525\u201330. https:\/\/doi.org\/10.1007\/s00296-011-2249-4.","journal-title":"Rheumatol Int"},{"key":"23_CR131","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fimmu.2016.00101","volume":"7","author":"CM Nielsen","year":"2016","unstructured":"Nielsen CM, Wolf A-S, Goodier MR, Riley EM. Synergy between common \u03b3 chain family cytokines and IL-18 potentiates innate and adaptive pathways of NK cell activation. Front Immunol. 2016;7:101. https:\/\/doi.org\/10.3389\/fimmu.2016.00101.","journal-title":"Front Immunol"},{"key":"23_CR132","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","volume":"4","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289. https:\/\/doi.org\/10.3389\/fimmu.2013.00289.","journal-title":"Front Immunol"},{"key":"23_CR133","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","volume":"141","author":"G Prencipe","year":"2018","unstructured":"Prencipe G, Caiello I, Pascarella A, et al. Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018;141:1439\u201349. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.021.","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR134","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/art.20268","volume":"50","author":"N Maeno","year":"2004","unstructured":"Maeno N, Takei S, Imanaka H, et al. Increased Interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004;50:1935\u20138. https:\/\/doi.org\/10.1002\/art.20268.","journal-title":"Arthritis Rheum"},{"key":"23_CR135","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1164\/rccm.201903-0659OC","volume":"201","author":"E Verweyen","year":"2020","unstructured":"Verweyen E, Holzinger D, Weinhage T, et al. Synergistic signaling of TLR and IFN\u03b1\/\u03b2 facilitates escape of IL-18 expression from endotoxin tolerance. Am J Respir Crit Care Med. 2020;201:526\u201339. https:\/\/doi.org\/10.1164\/rccm.201903-0659OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"23_CR136","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.bbrc.2006.02.096","volume":"342","author":"J Arimitsu","year":"2006","unstructured":"Arimitsu J, Hirano T, Higa S, et al. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun. 2006;342:1413\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2006.02.096.","journal-title":"Biochem Biophys Res Commun"},{"key":"23_CR137","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood.2019003846","volume":"136","author":"P Tsoukas","year":"2020","unstructured":"Tsoukas P, Rapp E, Van Der Kraak L, et al. Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation. Blood. 2020;136:2162\u201374. https:\/\/doi.org\/10.1182\/blood.2019003846.","journal-title":"Blood"},{"key":"23_CR138","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","volume":"139","author":"SW Canna","year":"2017","unstructured":"Canna SW, Girard C, Malle L, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139:1698\u2013701. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.022.","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR139","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin S, Fall N, Brown RA, et al. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford). 2020;59:361\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kez282.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR140","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/rheumatology\/keaa634","volume":"60","author":"M Mizuta","year":"2021","unstructured":"Mizuta M, Shimizu M, Inoue N, et al. Clinical significance of Interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60:2421\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/keaa634.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR141","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","volume":"49","author":"M Shimizu","year":"2010","unstructured":"Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of Interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49:1645\u201353. https:\/\/doi.org\/10.1093\/rheumatology\/keq133.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR142","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","volume":"106","author":"K Mazodier","year":"2005","unstructured":"Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106:3483\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-1980.","journal-title":"Blood"},{"key":"23_CR143","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","volume":"43","author":"JE Rood","year":"2023","unstructured":"Rood JE, Rezk A, Pogoriler J, et al. Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1\u03b2 and IL-18. J Clin Immunol. 2023;43:101\u20138. https:\/\/doi.org\/10.1007\/s10875-022-01353-y.","journal-title":"J Clin Immunol"},{"key":"23_CR144","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/blood-2015-07-659813","volume":"127","author":"JE Rood","year":"2016","unstructured":"Rood JE, Rao S, Paessler M, et al. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Blood. 2016;127:426\u201335. https:\/\/doi.org\/10.1182\/blood-2015-07-659813.","journal-title":"Blood"},{"key":"23_CR145","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/rheumatology\/keaa299","volume":"60","author":"M Mizuta","year":"2021","unstructured":"Mizuta M, Shimizu M, Irabu H, et al. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children. Rheumatology (Oxford). 2021;60:231\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keaa299.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR146","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1084\/jem.20170412","volume":"214","author":"A-M Cepika","year":"2017","unstructured":"Cepika A-M, Banchereau R, Segura E, et al. A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis. J Exp Med. 2017;214:3449\u201366. https:\/\/doi.org\/10.1084\/jem.20170412.","journal-title":"J Exp Med"},{"key":"23_CR147","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1038\/s41467-022-34480-6","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang Z, You X, Chen L, et al. mTORC1 links pathology in experimental models of Still\u2019s disease and macrophage activation syndrome. Nat Commun. 2022;13:6915. https:\/\/doi.org\/10.1038\/s41467-022-34480-6.","journal-title":"Nat Commun"},{"key":"23_CR148","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/art.37958","volume":"65","author":"SW Canna","year":"2013","unstructured":"Canna SW, Wrobel J, Chu N, et al. Interferon-\u03b3 mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum. 2013;65:1764\u201375. https:\/\/doi.org\/10.1002\/art.37958.","journal-title":"Arthritis Rheum"},{"key":"23_CR149","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/eji.200838488","volume":"38","author":"J Pachlopnik Schmid","year":"2008","unstructured":"Pachlopnik Schmid J, Ho C-H, Diana J, et al. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH). Eur J Immunol. 2008;38:3219\u201325. https:\/\/doi.org\/10.1002\/eji.200838488.","journal-title":"Eur J Immunol"},{"key":"23_CR150","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood.2020009499","volume":"137","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi V, Marsh RA, Zoref-Lorenz A, et al. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021;137:2337\u201346. https:\/\/doi.org\/10.1182\/blood.2020009499.","journal-title":"Blood"},{"key":"23_CR151","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1365-2567.2001.01243.x","volume":"103","author":"YB Sullivan","year":"2001","unstructured":"Sullivan YB, Landay AL, Zack JA, et al. Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. Immunology. 2001;103:270\u201380. https:\/\/doi.org\/10.1046\/j.1365-2567.2001.01243.x.","journal-title":"Immunology"},{"key":"23_CR152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239157","volume":"15","author":"AK Virdi","year":"2020","unstructured":"Virdi AK, Wallace J, Barbian H, et al. CD32 is enriched on CD4dimCD8bright T cells. PLoS One. 2020;15:e0239157. https:\/\/doi.org\/10.1371\/journal.pone.0239157.","journal-title":"PLoS One"},{"key":"23_CR153","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/apa.15973","volume":"110","author":"S Imashuku","year":"2021","unstructured":"Imashuku S, Morimoto A, Ishii E. Virus-triggered secondary hemophagocytic lymphohistiocytosis. Acta Paediatr. 2021;110:2729\u201336. https:\/\/doi.org\/10.1111\/apa.15973.","journal-title":"Acta Paediatr"},{"key":"23_CR154","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash G, Carrera DA, Shrivastav S, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127:1425\u201337. https:\/\/doi.org\/10.1172\/JCI90644.","journal-title":"J Clin Invest"},{"key":"23_CR155","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/s0022-3476(96)70160-9","volume":"129","author":"R Mouy","year":"1996","unstructured":"Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750\u20134. https:\/\/doi.org\/10.1016\/s0022-3476(96)70160-9.","journal-title":"J Pediatr"},{"key":"23_CR156","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145\u201359. https:\/\/doi.org\/10.1146\/annurev-med-061813-012806.","journal-title":"Annu Rev Med"},{"key":"23_CR157","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/emmm.200900009","volume":"1","author":"J Pachlopnik Schmid","year":"2009","unstructured":"Pachlopnik Schmid J, Ho C-H, Chr\u00e9tien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med. 2009;1:112\u201324. https:\/\/doi.org\/10.1002\/emmm.200900009.","journal-title":"EMBO Mol Med"},{"key":"23_CR158","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382:1811\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1911326.","journal-title":"N Engl J Med"},{"key":"23_CR159","doi-asserted-by":"publisher","first-page":"663329","DOI":"10.3389\/fimmu.2021.663329","volume":"12","author":"A Pascarella","year":"2021","unstructured":"Pascarella A, Bracaglia C, Caiello I, et al. Monocytes from patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis are hyperresponsive to interferon gamma. Front Immunol. 2021;12:663329. https:\/\/doi.org\/10.3389\/fimmu.2021.663329.","journal-title":"Front Immunol"},{"key":"23_CR160","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/annrheumdis-2020-217470","volume":"80","author":"GS Schulert","year":"2021","unstructured":"Schulert GS, Pickering AV, Do T, et al. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-\u03b3 hyper-responsiveness and risk for macrophage activation syndrome. Ann Rheum Dis. 2021;80:617\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217470.","journal-title":"Ann Rheum Dis"},{"key":"23_CR161","doi-asserted-by":"publisher","unstructured":"De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023. Epub 20230331. https:\/\/doi.org\/10.1136\/ard-2022-223739. PubMed PMID: 37001971.","DOI":"10.1136\/ard-2022-223739"},{"key":"23_CR162","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jaci.2014.11.030","volume":"135","author":"B Tesi","year":"2015","unstructured":"Tesi B, Sieni E, Neves C, et al. Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-\u03b3 receptor deficiency. J Allergy Clin Immunol. 2015;135:1638\u201341. https:\/\/doi.org\/10.1016\/j.jaci.2014.11.030.","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR163","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.4049\/jimmunol.2000652","volume":"205","author":"K Kidder","year":"2020","unstructured":"Kidder K, Bian Z, Shi L, Liu Y. Inflammation unrestrained by SIRP\u03b1 induces secondary hemophagocytic lymphohistiocytosis independent of IFN-\u03b3. J Immunol. 2020;205:2821\u201333. https:\/\/doi.org\/10.4049\/jimmunol.2000652.","journal-title":"J Immunol"},{"key":"23_CR164","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang W, O\u2019Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50:871\u201391. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.020.","journal-title":"Immunity"},{"key":"23_CR165","first-page":"912","volume":"28","author":"JC M\u00f6ller","year":"2010","unstructured":"M\u00f6ller JC, Paul D, Ganser G, et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol. 2010;28:912\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"23_CR166","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1182\/blood-2010-08-300046","volume":"117","author":"J Sumegi","year":"2011","unstructured":"Sumegi J, Barnes MG, Nestheide SV, et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011;117:e151\u201360. https:\/\/doi.org\/10.1182\/blood-2010-08-300046.","journal-title":"Blood"},{"key":"23_CR167","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jpeds.2021.02.008","volume":"235","author":"L Guo","year":"2021","unstructured":"Guo L, Xu Y, Qian X, et al. Sudden hypotension and increased serum interferon-\u03b3 and Interleukin-10 predict early macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Pediatr. 2021;235:203\u2013211.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2021.02.008.","journal-title":"J Pediatr"},{"key":"23_CR168","doi-asserted-by":"publisher","first-page":"R148","DOI":"10.1186\/ar2041","volume":"8","author":"MS Fife","year":"2006","unstructured":"Fife MS, Gutierrez A, Ogilvie EM, et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res Ther. 2006;8:R148. https:\/\/doi.org\/10.1186\/ar2041.","journal-title":"Arthritis Res Ther"},{"key":"23_CR169","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/art.40498","volume":"70","author":"VL Arthur","year":"2018","unstructured":"Arthur VL, Shuldiner E, Remmers EF, et al. IL1RN variation influences both disease susceptibility and response to recombinant human Interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018;70:1319\u201330. https:\/\/doi.org\/10.1002\/art.40498.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR170","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3899\/jrheum.121131","volume":"40","author":"M Gorelik","year":"2013","unstructured":"Gorelik M, Fall N, Altaye M, et al. Follistatin-like protein 1 and the ferritin\/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2013;40:1191\u20139. https:\/\/doi.org\/10.3899\/jrheum.121131.","journal-title":"J Rheumatol"},{"key":"23_CR171","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14397595.2016.1270795","volume":"27","author":"M Shimizu","year":"2017","unstructured":"Shimizu M, Nakagishi Y, Inoue N, et al. Leucine-rich \u03b12-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: a case series. Mod Rheumatol. 2017;27:833\u20137. https:\/\/doi.org\/10.1080\/14397595.2016.1270795.","journal-title":"Mod Rheumatol"},{"key":"23_CR172","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","volume":"79","author":"PJ Murray","year":"2017","unstructured":"Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541\u201366. https:\/\/doi.org\/10.1146\/annurev-physiol-022516-034339.","journal-title":"Annu Rev Physiol"},{"key":"23_CR173","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1128\/CVI.00306-10","volume":"18","author":"MF Ibarra","year":"2011","unstructured":"Ibarra MF, Klein-Gitelman M, Morgan E, et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol. 2011;18:609\u201314. https:\/\/doi.org\/10.1128\/CVI.00306-10.","journal-title":"Clin Vaccine Immunol"},{"key":"23_CR174","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3899\/jrheum.100655","volume":"38","author":"M Yanagimachi","year":"2011","unstructured":"Yanagimachi M, Naruto T, Miyamae T, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol. 2011;38:769\u201374. https:\/\/doi.org\/10.3899\/jrheum.100655.","journal-title":"J Rheumatol"},{"key":"23_CR175","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.1990","volume":"12","author":"T Krausgruber","year":"2011","unstructured":"Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011;12:231\u20138. https:\/\/doi.org\/10.1038\/ni.1990.","journal-title":"Nat Immunol"},{"key":"23_CR176","first-page":"21","volume":"42","author":"S Goel","year":"2012","unstructured":"Goel S, Polski JM, Imran H. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis. Ann Clin Lab Sci. 2012;42:21\u20135.","journal-title":"Ann Clin Lab Sci"},{"key":"23_CR177","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jlb.67.1.97","volume":"67","author":"C Buechler","year":"2000","unstructured":"Buechler C, Ritter M, Ors\u00f3 E, et al. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 2000;67:97\u2013103.","journal-title":"J Leukoc Biol"},{"key":"23_CR178","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/art.38379","volume":"66","author":"SW Canna","year":"2014","unstructured":"Canna SW, Costa-Reis P, Bernal WE, et al. Brief report: alternative activation of laser-captured murine hemophagocytes. Arthritis Rheumatol. 2014;66:1666\u201371. https:\/\/doi.org\/10.1002\/art.38379.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR179","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958\u201369. https:\/\/doi.org\/10.1038\/nri2448.","journal-title":"Nat Rev Immunol"},{"key":"23_CR180","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.20102538","volume":"208","author":"EE Zoller","year":"2011","unstructured":"Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med. 2011;208:1203\u201314. https:\/\/doi.org\/10.1084\/jem.20102538.","journal-title":"J Exp Med"},{"key":"23_CR181","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1182\/blood-2012-02-408864","volume":"120","author":"T Kuriyama","year":"2012","unstructured":"Kuriyama T, Takenaka K, Kohno K, et al. Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. Blood. 2012;120:4058\u201367. https:\/\/doi.org\/10.1182\/blood-2012-02-408864.","journal-title":"Blood"},{"key":"23_CR182","doi-asserted-by":"publisher","first-page":"eabj5501","DOI":"10.1126\/sciimmunol.abj5501","volume":"7","author":"D Li","year":"2022","unstructured":"Li D, Xiong W, Wang Y, et al. SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors. Sci Immunol. 2022;7:eabj5501. https:\/\/doi.org\/10.1126\/sciimmunol.abj5501.","journal-title":"Sci Immunol"},{"key":"23_CR183","doi-asserted-by":"publisher","first-page":"eaao5213","DOI":"10.1126\/science.aao5213","volume":"363","author":"HM Akilesh","year":"2019","unstructured":"Akilesh HM, Buechler MB, Duggan JM, et al. Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes. Science. 2019;363:eaao5213. https:\/\/doi.org\/10.1126\/science.aao5213.","journal-title":"Science"},{"key":"23_CR184","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1073\/pnas.1820704116","volume":"116","author":"A Wang","year":"2019","unstructured":"Wang A, Pope SD, Weinstein JS, et al. Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice. Proc Natl Acad Sci USA. 2019;116:2200\u20139. https:\/\/doi.org\/10.1073\/pnas.1820704116.","journal-title":"Proc Natl Acad Sci USA"},{"key":"23_CR185","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.immuni.2013.06.019","volume":"39","author":"H Ohyagi","year":"2013","unstructured":"Ohyagi H, Onai N, Sato T, et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity. 2013;39:584\u201398. https:\/\/doi.org\/10.1016\/j.immuni.2013.06.019.","journal-title":"Immunity"},{"key":"23_CR186","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2019-216030","volume":"79","author":"PY Lee","year":"2020","unstructured":"Lee PY, Schulert GS, Canna SW, et al. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79:225\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216030.","journal-title":"Ann Rheum Dis"},{"key":"23_CR187","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1002\/art.22981","volume":"56","author":"N Fall","year":"2007","unstructured":"Fall N, Barnes M, Thornton S, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56:3793\u2013804. https:\/\/doi.org\/10.1002\/art.22981.","journal-title":"Arthritis Rheum"},{"key":"23_CR188","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cyto.2012.05.003","volume":"60","author":"M Shimizu","year":"2012","unstructured":"Shimizu M, Yachie A. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages. Cytokine. 2012;60:226\u201332. https:\/\/doi.org\/10.1016\/j.cyto.2012.05.003.","journal-title":"Cytokine"},{"key":"23_CR189","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2741\/2692","volume":"13","author":"FO Martinez","year":"2008","unstructured":"Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453\u201361. https:\/\/doi.org\/10.2741\/2692.","journal-title":"Front Biosci"},{"key":"23_CR190","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clim.2011.12.008","volume":"142","author":"C Macaubas","year":"2012","unstructured":"Macaubas C, Nguyen KD, Peck A, et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol. 2012;142:362\u201372. https:\/\/doi.org\/10.1016\/j.clim.2011.12.008.","journal-title":"Clin Immunol"},{"key":"23_CR191","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/ncprheum0919","volume":"4","author":"A Kelly","year":"2008","unstructured":"Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615\u201320. https:\/\/doi.org\/10.1038\/ncprheum0919.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"23_CR192","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/RHU.0b013e318205092d","volume":"17","author":"N Bruck","year":"2011","unstructured":"Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17:23\u20137. https:\/\/doi.org\/10.1097\/RHU.0b013e318205092d.","journal-title":"J Clin Rheumatol"},{"key":"23_CR193","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with Interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50:417.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR194","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3899\/jrheum.091046","volume":"37","author":"M Durand","year":"2010","unstructured":"Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37:879\u201380. https:\/\/doi.org\/10.3899\/jrheum.091046.","journal-title":"J Rheumatol"},{"key":"23_CR195","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1136\/annrheumdis-2020-216983","volume":"81","author":"B Bader-Meunier","year":"2022","unstructured":"Bader-Meunier B, Hadchouel A, Berteloot L, et al. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report. Ann Rheum Dis. 2022;81:e20. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216983.","journal-title":"Ann Rheum Dis"},{"key":"23_CR196","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217390","volume":"81","author":"S Sato","year":"2022","unstructured":"Sato S, Hosokawa T, Kawashima H. Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease. Ann Rheum Dis. 2022;81:e61. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217390.","journal-title":"Ann Rheum Dis"},{"key":"23_CR197","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3899\/jrheum.121098","volume":"40","author":"PJ Kahn","year":"2013","unstructured":"Kahn PJ, Cron RQ. Higher-dose anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol. 2013;40:743\u20134. https:\/\/doi.org\/10.3899\/jrheum.121098.","journal-title":"J Rheumatol"},{"key":"23_CR198","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006656","volume":"96","author":"F Parisi","year":"2017","unstructured":"Parisi F, Paglionico A, Varriano V, et al. Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8\u200amg\/kg\/d) of anakinra. Medicine (Baltimore). 2017;96:e6656. https:\/\/doi.org\/10.1097\/MD.0000000000006656.","journal-title":"Medicine (Baltimore)"},{"key":"23_CR199","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","volume":"271","author":"CJ Fisher","year":"1994","unstructured":"Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994;271:1836\u201343.","journal-title":"JAMA"},{"key":"23_CR200","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","volume":"25","author":"SM Opal","year":"1997","unstructured":"Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory Interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25:1115\u201324. https:\/\/doi.org\/10.1097\/00003246-199707000-00010.","journal-title":"Crit Care Med"},{"key":"23_CR201","first-page":"451","volume":"11","author":"JL St\u00e9phan","year":"1993","unstructured":"St\u00e9phan JL, Zeller J, Hubert P, et al. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993;11:451\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"23_CR202","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/s0022-3476(96)70408-0","volume":"128","author":"A Ravelli","year":"1996","unstructured":"Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128:275\u20138. https:\/\/doi.org\/10.1016\/s0022-3476(96)70408-0.","journal-title":"J Pediatr"},{"key":"23_CR203","first-page":"508","volume":"97","author":"B Quesnel","year":"1997","unstructured":"Quesnel B, Catteau B, Aznar V, et al. Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF. Br J Haematol. 1997;97:508\u201310.","journal-title":"Br J Haematol"},{"key":"23_CR204","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/MPH.0b013e3181923cb4","volume":"31","author":"AA Gupta","year":"2009","unstructured":"Gupta AA, Tyrrell P, Valani R, et al. Experience with hemophagocytic lymphohistiocytosis\/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol. 2009;31:81\u20134. https:\/\/doi.org\/10.1097\/MPH.0b013e3181923cb4.","journal-title":"J Pediatr Hematol Oncol"},{"key":"23_CR205","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/pbc.21019","volume":"50","author":"B Makay","year":"2008","unstructured":"Makay B, Yilmaz S, T\u00fcrkyilmaz Z, et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer. 2008;50:419\u201321. https:\/\/doi.org\/10.1002\/pbc.21019.","journal-title":"Pediatr Blood Cancer"},{"key":"23_CR206","first-page":"2120","volume":"28","author":"S Prahalad","year":"2001","unstructured":"Prahalad S, Bove KE, Dickens D, et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120\u20134.","journal-title":"J Rheumatol"},{"key":"23_CR207","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4414\/smw.2002.10031","volume":"132","author":"D Aeberli","year":"2002","unstructured":"Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002;132:414\u201322. https:\/\/doi.org\/10.4414\/smw.2002.10031.","journal-title":"Swiss Med Wkly"},{"key":"23_CR208","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/00124743-200108000-00013","volume":"7","author":"A Stern","year":"2001","unstructured":"Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still\u2019s disease after initiation of etanercept therapy. J Clin Rheumatol. 2001;7:252\u20136. https:\/\/doi.org\/10.1097\/00124743-200108000-00013.","journal-title":"J Clin Rheumatol"},{"key":"23_CR209","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119\u201322. https:\/\/doi.org\/10.1097\/PPO.0000000000000035.","journal-title":"Cancer J"},{"key":"23_CR210","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/rheumatology\/keu019","volume":"53","author":"E Savage","year":"2014","unstructured":"Savage E, Wazir T, Drake M, et al. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still\u2019s disease successfully treated with tocilizumab. Rheumatology (Oxford). 2014;53:1352\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/keu019.","journal-title":"Rheumatology (Oxford)"},{"key":"23_CR211","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.2169\/internalmedicine.54.4935","volume":"54","author":"D Kobayashi","year":"2015","unstructured":"Kobayashi D, Ito S, Murasawa A, et al. Two cases of adult-onset Still\u2019s disease treated with tocilizumab that achieved tocilizumab-free remission. Intern Med. 2015;54:2675\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.54.4935.","journal-title":"Intern Med"},{"key":"23_CR212","doi-asserted-by":"publisher","first-page":"5656320","DOI":"10.1155\/2016\/5656320","volume":"2016","author":"E Watanabe","year":"2016","unstructured":"Watanabe E, Sugawara H, Yamashita T, et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still\u2019s disease: a case-based review. Case Rep Med. 2016;2016:5656320. https:\/\/doi.org\/10.1155\/2016\/5656320.","journal-title":"Case Rep Med"},{"key":"23_CR213","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/mr\/roab119","volume":"32","author":"J Wu","year":"2022","unstructured":"Wu J, Sun L, Tang X, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis\u2013associated refractory macrophage activation syndrome. Mod Rheumatol. 2022;32:1114\u201321. https:\/\/doi.org\/10.1093\/mr\/roab119.","journal-title":"Mod Rheumatol"},{"key":"23_CR214","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/bjh.12386","volume":"162","author":"D Chellapandian","year":"2013","unstructured":"Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162:376\u201382. https:\/\/doi.org\/10.1111\/bjh.12386.","journal-title":"Br J Haematol"},{"key":"23_CR215","doi-asserted-by":"publisher","first-page":"bcr2016216488","DOI":"10.1136\/bcr-2016-216488","volume":"2016","author":"C Stefanou","year":"2016","unstructured":"Stefanou C, Tzortzi C, Georgiou F, Timiliotou C. Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review. BMJ Case Rep. 2016;2016:bcr2016216488. https:\/\/doi.org\/10.1136\/bcr-2016-216488.","journal-title":"BMJ Case Rep"},{"key":"23_CR216","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00043426-200210000-00011","volume":"24","author":"L Sung","year":"2002","unstructured":"Sung L, King SM, Carcao M, et al. Adverse outcomes in primary hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2002;24:550\u20134. https:\/\/doi.org\/10.1097\/00043426-200210000-00011.","journal-title":"J Pediatr Hematol Oncol"},{"key":"23_CR217","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/BF02982023","volume":"75","author":"S Imashuku","year":"2002","unstructured":"Imashuku S, Teramura T, Kuriyama K, et al. Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Int J Hematol. 2002;75:174\u20137. https:\/\/doi.org\/10.1007\/BF02982023.","journal-title":"Int J Hematol"},{"key":"23_CR218","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl S, Astigarraga I, von Bahr GT, et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018;6:1508\u201317. https:\/\/doi.org\/10.1016\/j.jaip.2018.05.031.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"23_CR219","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2009.02.005","volume":"132","author":"A Coca","year":"2009","unstructured":"Coca A, Bundy KW, Marston B, et al. Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol. 2009;132:10\u20138. https:\/\/doi.org\/10.1016\/j.clim.2009.02.005.","journal-title":"Clin Immunol"},{"key":"23_CR220","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398:1984\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1.","journal-title":"Lancet"},{"key":"23_CR221","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/ecco-jcc\/jjaa009","volume":"14","author":"MC Barnhoorn","year":"2020","unstructured":"Barnhoorn MC, Hakuno SK, Bruckner RS, et al. Stromal cells in the pathogenesis of inflammatory bowel disease. J Crohns Colitis. 2020;14:995\u20131009. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa009.","journal-title":"J Crohns Colitis"},{"key":"23_CR222","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s12079-018-0486-y","volume":"12","author":"MY Bhat","year":"2018","unstructured":"Bhat MY, Solanki HS, Advani J, et al. Comprehensive network map of interferon gamma signaling. J Cell Commun Signal. 2018;12:745\u201351. https:\/\/doi.org\/10.1007\/s12079-018-0486-y.","journal-title":"J Cell Commun Signal"},{"key":"23_CR223","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","volume":"127","author":"R Das","year":"2016","unstructured":"Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127:1666\u201375. https:\/\/doi.org\/10.1182\/blood-2015-12-684399.","journal-title":"Blood"},{"key":"23_CR224","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1182\/blood.2020007930","volume":"138","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi V, Lakes N, Tran M, et al. JAK inhibition for murine HLH requires complete blockade of IFN-\u03b3 signaling and is limited by toxicity of JAK2 inhibition. Blood. 2021;138:1034\u20139. https:\/\/doi.org\/10.1182\/blood.2020007930.","journal-title":"Blood"},{"key":"23_CR225","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","volume":"1","author":"L Broglie","year":"2017","unstructured":"Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1:1533\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2017007526.","journal-title":"Blood Adv"},{"key":"23_CR226","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/ejh.13593","volume":"106","author":"S Hansen","year":"2021","unstructured":"Hansen S, Alduaij W, Biggs CM, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series. Eur J Haematol. 2021;106:654\u201361. https:\/\/doi.org\/10.1111\/ejh.13593.","journal-title":"Eur J Haematol"},{"key":"23_CR227","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaci.2022.07.026","volume":"151","author":"J-A Joly","year":"2023","unstructured":"Joly J-A, Vall\u00e9e A, Bourdin B, et al. Combined IFN-\u03b3 and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice. J Allergy Clin Immunol. 2023;151:247\u2013259.e7. https:\/\/doi.org\/10.1016\/j.jaci.2022.07.026.","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR228","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.hjc.2022.11.001","volume":"69","author":"MI Barrionuevo-S\u00e1nchez","year":"2023","unstructured":"Barrionuevo-S\u00e1nchez MI, Ariza-Sol\u00e9 A, Prado ND, et al. Impact of shock aetiology and hospital characteristics on the clinical profile, management and prognosis of patients with non ACS-related cardiogenic shock. Hell J Cardiol. 2023;69:16\u201323. https:\/\/doi.org\/10.1016\/j.hjc.2022.11.001.","journal-title":"Hell J Cardiol"},{"key":"23_CR229","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pbc.24188","volume":"60","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60:101\u20139. https:\/\/doi.org\/10.1002\/pbc.24188.","journal-title":"Pediatr Blood Cancer"},{"key":"23_CR230","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","volume":"2","author":"JMF Silva","year":"2018","unstructured":"Silva JMF, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2018;2:777\u201386. https:\/\/doi.org\/10.1182\/bloodadvances.2017014449.","journal-title":"Blood Adv"},{"key":"23_CR231","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.transci.2016.09.015","volume":"55","author":"M Bosnak","year":"2016","unstructured":"Bosnak M, Erdogan S, Aktekin EH, Bay A. Therapeutic plasma exchange in primary hemophagocytic lymphohistiocytosis: reports of two cases and a review of the literature. Transfus Apher Sci. 2016;55:353\u20136. https:\/\/doi.org\/10.1016\/j.transci.2016.09.015.","journal-title":"Transfus Apher Sci"},{"key":"23_CR232","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009283","volume":"96","author":"C Nusshag","year":"2017","unstructured":"Nusshag C, Morath C, Zeier M, et al. Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis: a case report and review of the literature. Medicine (Baltimore). 2017;96:e9283. https:\/\/doi.org\/10.1097\/MD.0000000000009283.","journal-title":"Medicine (Baltimore)"},{"key":"23_CR233","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1744-9987.2009.00607.x","volume":"13","author":"H Nakakura","year":"2009","unstructured":"Nakakura H, Ashida A, Matsumura H, et al. A case report of successful treatment with plasma exchange for hemophagocytic syndrome associated with severe systemic juvenile idiopathic arthritis in an infant girl. Ther Apher Dial. 2009;13:71\u20136. https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00607.x.","journal-title":"Ther Apher Dial"},{"key":"23_CR234","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/cc11256","volume":"16","author":"D Demirkol","year":"2012","unstructured":"Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction syndrome\/macrophage activation syndrome: what is the treatment? Crit Care. 2012;16:R52. https:\/\/doi.org\/10.1186\/cc11256.","journal-title":"Crit Care"},{"key":"23_CR235","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00296-022-05231-z","volume":"43","author":"E Liquidano-Perez","year":"2023","unstructured":"Liquidano-Perez E, Maza-Ramos G, Salazar-Bail\u00f3n JL, et al. Therapeutic plasma exchange in refractory macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a case-based review. Rheumatol Int. 2023;43:183\u20139. https:\/\/doi.org\/10.1007\/s00296-022-05231-z.","journal-title":"Rheumatol Int"},{"key":"23_CR236","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3899\/jrheum.100726","volume":"38","author":"JL Record","year":"2011","unstructured":"Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38:180\u20131. https:\/\/doi.org\/10.3899\/jrheum.100726.","journal-title":"J Rheumatol"},{"key":"23_CR237","doi-asserted-by":"publisher","unstructured":"De Benedetti F, Grom AA, Brogan P, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. medRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.12.12.22283141.","DOI":"10.1101\/2022.12.12.22283141"},{"key":"23_CR238","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2012.00239","volume":"3","author":"L Chiossone","year":"2012","unstructured":"Chiossone L, Audonnet S, Chetaille B, et al. Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol. 2012;3:239. https:\/\/doi.org\/10.3389\/fimmu.2012.00239.","journal-title":"Front Immunol"},{"key":"23_CR239","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis. 2018;77:840\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212608.","journal-title":"Ann Rheum Dis"},{"key":"23_CR240","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.40071","volume":"69","author":"EM Behrens","year":"2017","unstructured":"Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol. 2017;69:1135\u201343. https:\/\/doi.org\/10.1002\/art.40071.","journal-title":"Arthritis Rheumatol"},{"key":"23_CR241","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaci.2020.09.016","volume":"146","author":"SW Canna","year":"2020","unstructured":"Canna SW, Cron RQ. Highways to hell: mechanism-based management of cytokine storm syndromes. J Allergy Clin Immunol. 2020;146:949\u201359. https:\/\/doi.org\/10.1016\/j.jaci.2020.09.016.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Advances in Experimental Medicine and Biology","Cytokine Storm Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-59815-9_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:05:56Z","timestamp":1723154756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-59815-9_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031598142","9783031598159"],"references-count":241,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-59815-9_23","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"9 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}